Knockdown studies of CHRDL2 have been shown to inhibit proliferation and migration in CRC, gastric cancer and osteosarcoma, and overexpression promotes cellular proliferation, migration and clonogenicity [27, 30]. Here, CHRDL2 is linked to osteosarcoma.